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ABSTRACT: A Clinical trial of Indigenous compound drug ‘Nishamalaki’ was carried out in 
the CRI (Ayurveda) Hospital, Jaipur on the patient of Madhumeha.  For this study, patients were 
randomly divided into two groups of 25 individuals each and they were termed as group A and 
B. The individuals of group a were administered Nishamalaki in a dose of one gram twice daily 
along with diet control, the patients were followed every fort nightly.  A significant improvement 
in the symptoms along with lowering of blood glucose level was observed in the individuals of 
group B, while the individuals of group A responded initially but could not sustain the same. 
 
INTRODUCTION: 
 
Madhumeha, often correlated with Diabetes 
Mellitus stands as a global problem.   
Diabetes Mellitus is the most common of the 
serious metabolic diseases.  When a patient 
presents sign and symptoms attributable to 
an osmotic diuresis and is found to have 
hyperglycemia, essentially all the physicians 
agree that Diabetes is present.  It was well 
known to the ancient Indian Physicians who 
described not only the sweet taste of urine as 
one of the major symptoms but also the 
relationship of the disease with obesity and 
consequences of bio-chemical abnormalities 
in the body creating dislipidaemia in the 
glucose metabolism. 
 
An elaborate description of its clinical 
features and effective management are seen 
in classical texts.  A number of herbal 
preparations and plant extracts have been 
used with varying degree of success in the 
management of NIDDM.  In the present 
study on herbal preparation viz.   
Nishamalaki was taken under trial and its 
effects on clinical features, blood and urine 
sugar levels was assessed. 
 
MATERIAL AND METHODS: 
 
1.  Selection of cases:- Clinical trail of the 
drug was carried out in the CRI(Ay.). 
hospital at Jaipur. 
 
Patients belonging to the near by areas 
of Jaipur were selected to ensure regular 
follow up. 
 
•  Patients were randomly divided in two 
groups. Group A and B the groups 
contained 25 patients having at least two 
follow up. All the patients were between 
age group of 30 to 70 yrs. Having 
diagnosed as NIDDM. 
•  Patients of group – A were administered 
a placebo (Barley Powder) in a dose of 
one gram thrice daily for six weeks 
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along with diet control and they were 
followed every Fortnightly. 
•  Patients of group B were …. Every 
fortnightly. 
•  Patients diagnosed as IDDM and 
individuals having systematic 
complications were considered unfit for 
the studies. 
 
H. Parameters for Assessment: 
 
•  Clinical parameters: Certain classical 
sign and symptoms based on the 
protocol cleared by the respective ethical 
committee of CCRAS were taken up for 
study e.g. Prabhutamutrata (polyuria), 
avilamutrata (Turbid urine), 
Kshudhadhikya (Poly phagia) Trisha 
(Polydypsia) and Sthaulya (obesity). 
Symptoms were graded as ‘O’ (Nil), ‘4’ 
(Mild), ‘7’ (Moderate and ‘10’ as severe  
•  Sthaulya was assessed on the basis of 
ponderal index. (cm.kg.) 
 
Pathological parameters :- 
 
•  Value of fasting blood sugar and PPBS. 
(Before and after treatment) 
 
•  Urine sugar (Before and after treatment) 
 
Treatment Response:- 
 
Response of the treatment was observed on 
the basis of improvement in clinical features 
Blood and Urine sugar levels after one 
month of therapy. 
 
RESULTS AND OBSERVATION 
TABLE NO.1. INCIDENCE OF AGE & SEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
*n= 25 Table shows that most of the patient in both the groups were in the age group of 41-50yrs. 
 
Table No.2-Incidence of dosa prakriti. 
 
S.No  Prakriti  Group -A  Group –B 
1. 
2. 
3. 
4. 
5. 
6. 
V 
P 
K 
V-P 
V-K 
P-K 
1(4%) 
3(12%) 
1(4%) 
6(24%) 
6(24%) 
6(24%) 
1(4%) 
2(8%) 
2(8%) 
5(20%) 
7(28%) 
7(28%) 
S.No.  Age group (Yrs.)  Group  Male  Female 
1. 
 
2. 
 
3. 
 
4. 
31-40 
 
41-50 
 
51-60 
 
61-70 
A 
B 
A 
B 
A 
B 
A 
B 
5(20%) 
3(12%) 
8(32%) 
9(36%) 
3(12%) 
5(20%) 
- 
1(4%) 
1(4%) 
 
3(12%) 
2(8%) 
4(16%) 
2(8%) 
1(4%) 
3(12%) 
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7. S  2(8%)  1(4%) 
 
         *n= The table shows that Dvandaja Prakriti was predominant in both groups. 
 
Table No.3 
INCIDENCE OF MANASPRAKRITI 
    
 
 
 
 
 
 
 
n = 25 Most of the patient have Rajo guna pradhana, Manas Prakriti 
 
Table No-4-Incidence of severity of symptoms (BT) 
 
S.No.  Symptoms  Group A  Group B 
   Nil  Mild  Mod.  Severe  Nil  Mild  Mod.  Severe 
1. PradhutaMutra  0 
(0.0%) 
4 
(16.0%)
18 
(72%)
3 
(12.0%)
2 
(8.0%)
5 
(20%) 
14 
(56.0%) 
4 
(16.0%)
2. Avil  Mutrata  16 
(64%) 
6 
(24%) 
2 
(8%) 
1 
(4%) 
18 
(72%) 
5 
(20%) 
2 
(8%) 
O 
(0%) 
3. Kshudhadhikya  0 
(0%) 
7 
(28%) 
15 
(60%)
3 
(12%)  
6 
(24%) 
5 
(20%) 
12 
(48%) 
2 
(8%) 
4. Trisha  1 
(4%) 
8 
(32%) 
11 
(44%)
5 
(20%) 
3 
(12%) 
9 
(36%) 
11 
(44%) 
2 
(8%) 
 
*n=25; BT-Before Treatment  
 
Table No-5-Incidence of severity of symptoms (AT) 
 
S.No.  Symptoms  Group A  Group B 
    Nil Mild  Mod.  Severe Nil Mild Mod.  Severe 
1. PradhutaMutra  1 
(4%) 
12 
(48%)
8 
(32%)
4 
(16%) 
2 
(8%) 
16 
(64%) 
7 
(28%) 
0 
(0%) 
2. Avil  Mutrata  17 
(68%) 
8 
(32%)
0 
(0%) 
0 
(0%) 
20 
(80%)
4 
(16%) 
1 
(4%) 
0 
(0%) 
3. Kshudhadhikya  1 
(4%) 
17 
(68%)
7 
(28%)
0 
(0%) 
7 
(28%)
14 
(56%) 
3 
(12%) 
1 
(4%) 
4. Trisha  1 
(4%) 
5 
(60%)
9 
(36%)
0 
(0%) 
6 
(24%)
13 
(52%) 
6 
(24%) 
0 
(0%) 
 
*n=25; AT-After Treatment  
 
 
S.No. M.  Prakriti 
(on basis of 
Predominence) 
Group - A  Group - B 
1. 
2. 
3. 
Sattva 
Raja 
Tama 
9(36%) 
15(60%) 
1(4%) 
10(40%) 
14(56%) 
1(4%) 
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Table No. 6. – Mean symptom score (BT & AT) 
 
S.No.  Symptoms  Group A  Group - B 
   BT  AT(1)  AT(2)  BT  AT(1)  AT(2) 
1. PradhutaMutra  6.88  6.40  5.80  6.32 5.36  4.52 
2. Avil  Mutrata 1.92  1.80  1.28  1.36 1.24  0.92 
3. Kshudhadhikya  6.52  5.32  4.68  4.96 4.12  3.48 
4. Trisha  6.36  5.40  4.92  5.32 4.68  3.76 
 
N=25; BT-Before Treatment; After Treatment 
 
Table No -7 Showing significance of the treatment on symptoms (Group B) 
 
S.No. Symptoms  X 
difference 
SD(+) SE(+)  t  P 
1. PradhutaMutra  1.80  2.28  0.46  3.913  <.001***
2. Avil  Mutrata 0.44  2.68  0.54  0.814  <.4 
3. Kshudhadhikya  1.48  2.95  0.59  2.508  <.02* 
4. Trisha  1.56  2.59  0.52  3.000  <.01** 
 
N= 25;*** Highly significant, ** Significant, *Less significant  
 
Table No -8 Showing significance of the treatment on symptoms (Group A) 
 
S.No. Symptoms  X 
difference 
SD(+) SE(+)  t  P 
1. PradhutaMutra  1.80  1.87  0.47  2.297  <.05* 
2. Avil  Mutrata 0.64  2.40  0.48  1.333  <.2 
3. Kshudhadhikya  1.04  1.76  0.56  1.857  >.1 
4. Trisha  1.14  2.16  0.54  2.111  <.05 
 
N= 25;*less significant  
 
Table No. 9: Treatment response on sthaulya (Based on ponderal Index) 
 
S.No Group  Before  treatment After  treatment 
1. 
2. 
A (25) 
B(25) 
4.558 
4.983 
4.498 
4.856 
  
The table shows mean ponderal Index (CM/kg.) of both the groups. 
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Table no.10; Treatment response on Urine Sugar level (Before & After Treatment) 
 
S.No Group    Nil 
(0) 
Mild 
(+) 
Moderate 
(+ +) 
Severe 
(+ + +) 
1. A 
(25) 
BT 6 
(24%) 
7 
(28%) 
10 
(40%) 
2 
(8%) 
  A T   8  
(32%) 
9 
(36%) 
7 
(28%) 
1 
(4%) 
2. B 
(25) 
BT 7 
(28%) 
6 
(24%) 
9 
(36%) 
3 
(12%) 
  AT  10 
(40%) 
8 
(32%) 
5 
(20%) 
2 
(8%) 
 
Table – 11; Treatment response on Blood sugar level 
 
S.No Group  FBS  PPBS 
    X diff.  SE  t  p  X diff.  SE  t  p 
1. Group  A 
(n=25) 
13.83 12.3  1.124  >.2  20.28 19.98  1.015 >.3 
2. Group  B 
(n=25) 
13.96 8.08  1.178  <.1*  18.64 13.53  1.378 <.1* 
 
* less significant 
 
Table – 12 ; Influence of Prakriti on Blood sugar (Group – B) 
 
S.No Prakriti  FBS  PPBS 
    X diff.  SE  T  P  X diff.  SE  T  P 
1. Vataja 
(n=1) 
2.0  - - -  4.0  - - - 
2. Pittaja 
(n=1) 
18.5 69.25  .267 NS  19.0 83.0 0.229  NS 
3. Kaphaja 
(n=2) 
24.0 2.0  12.0 <.001**  17  7.5  2.267  <.1* 
4. V-P 
(n=5) 
8.4  20.84 0.40  >.7  15  36.18 0.414 <.7 
5. V-K 
(n=7) 
24.28 11.52 2.10  <.1*  22  19.16 1.148 >.3 
6. P-K 
(n=7) 
12.29 10.43 1.17  >.2  14.29 12.47 1.145 >.3 
7. Sama 
(n=1) 
14  - - -  - - - - 
 
*less significant ** highly significant  
 
 
 
pages 18 - 24  6
 
Table – 13 ; Influence of Prakriti on Blood sugar (Group – A) 
 
S.No Prakriti  FBS  PPBS 
    X diff.  SE  T  P  X diff.  SE  T  P 
1. Vataja 
(n=1) 
30.0 -  -  -  50.0 -  -  - 
2. Pittaja 
(n=3) 
10.0 47.25  .212 NS  12.0 35.3 0.338  NS 
3. Kaphaja 
(n=1) 
30.0 -  -  -  19.0 -  -  - 
4. V-P 
(n=6) 
1.0 14.67  0.068  NS  7.5 23  0.326  NS 
5. V-K 
(n=6) 
11.0 9.08 1.211  >.3  13.66  5.72 2.388  <0.05 
6. P-K 
(n=6) 
21.0  15.51 1.354 >.3  32.83 21.64 1.517  >.2 
7. Sama 
(n=2) 
32.5 11.75  2.765  >.2  39.0 25.5 1.529  >.2 
 
DISCUSSION: 
 
•  The indigenous compound drug 
Nishamalaki selected for clinical trial is 
a combination of Haridra (Curcuma 
longa) and amalaki (Emblica officinalis), 
also advocated by Vagbhata as a drug of 
choice for the treatment of prameha.   
Shamaka properties.  Haridra is well 
known as a blood purifier while the 
Amalaki has a potent Rasayana effect. 
 
•  Group B, in general showed better 
response to the treatment considering 
symatology and decrease in the level of 
blood and urine sugar. This indicates the 
efficacy of drug as hypoglycemic agent. 
 
•  Patients with NIDDM have two 
physiologic defects, abnormal insulin 
secretion and resistance to insulin action 
in target tissues. 
 
•  Insulin resistance may be due to any one 
of three general causes; an abnormal 
insulin molecule, an excessive amount of 
circulting anti bodies and target tissue 
defects. 
 
•  It may be possible that this medicine 
may have some role against circulating 
antagonists and on the target tissue 
defects. Both the medicines included in 
the compound have Tridosa shamaka 
AND Rasayana property.  They are 
acting at the level of Rasa, Agni and 
Srotas, thus they may exert a positive 
response on the whole system 
 
•  Response of the treatment was found 
better among the individuals having 
Kaphja content in their body 
constitution, favours the better prognosis 
of Kapahaja prameha as described in the 
classics. 
 
•  No untoward effect was observed during 
the period of therapy. 
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CONCLUSION:- 
 
The drug Nishamalaki seems to be a simple, 
safe and cost effective remedy for the 
treatment of Diabetes mellitus. It may not be 
so useful in the individuals having fasting 
blood sugar levels above 200 mg%. In such 
condition oral hypoglycemic agent may be 
added.  Having high safety profile this drug 
may also be used as adjuvant along with the 
modern oral hypoglycemic agents. 
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